Division of Clinical Cancer Genomics, City of Hope, Duarte, California.
Clinical Cancer Genomics Community Research Network, Los Angeles, California.
Cancer. 2019 Aug 15;125(16):2829-2836. doi: 10.1002/cncr.32083. Epub 2019 Jun 17.
Breast cancer (BC) is the most common cancer and related cause of mortality among Hispanics, yet susceptibility has been understudied. BRCA1 and BRCA2 (BRCA) mutations explain less than one-half of hereditary BC, and the proportion associated with other BC susceptibility genes is unknown.
Germline DNA from 1054 BRCA-mutation-negative Hispanic women with hereditary BC (BC diagnosed at age <51 years, bilateral BC, breast and ovarian cancer, or BC diagnosed at ages 51-70 years with ≥2 first-degree or second-degree relatives who had BC diagnosed at age <70 years), 312 local controls, and 887 multiethnic cohort controls was sequenced and analyzed for 12 known and suspected, high-penetrance and moderate-penetrance cancer susceptibility genes (ataxia telangiectasia mutated [ATM], breast cancer 1 interacting protein C-terminal helicase 1 [BRIP1], cadherin 1 [CDH1], checkpoint kinase 2 [CHEK2], nibrin [NBN], neurofibromatosis type 1 [NF1], partner and localizer of BRCA2 [PALB2], phosphatase and tensin homolog [PTEN], RAD51 paralog 3 [RAD51C], RAD51D, serine/threonine kinase 11 [STK11], and TP53).
Forty-nine (4.6%) pathogenic or likely pathogenic variants (PVs) in 47 of 1054 participants (4.5%), including 21 truncating frameshift, 20 missense, 5 nonsense, and 4 splice variants, were identified in CHEK2 (n = 20), PALB2 (n = 18), ATM (n = 5), TP53 (n = 3), BRIP1 (n = 2), and CDH1 and NF1 (both n = 1) and none were identified in NBN, PTEN, STK11, RAD51C, or RAD51D. Nine participants carried the PALB2 c.2167_2168del PV (0.85%), and 14 carried the CHEK2 c.707T>C PV (1.32%).
Of 1054 BRCA-negative, high-risk Hispanic women, 4.5% carried a PV in a cancer susceptibility gene, increasing understanding of hereditary BC in this population. Recurrent PVs in PALB2 and CHEK2 represented 47% (23 of 49) of the total, suggesting a founder effect. Accurate classification of variants was enabled by carefully controlling for ancestry and the increased identification of at-risk Hispanics for screening and prevention.
乳腺癌(BC)是西班牙裔人群中最常见的癌症和相关死亡原因,但易感性研究较少。BRCA1 和 BRCA2(BRCA)突变解释了不到一半的遗传性 BC,而与其他 BC 易感性基因相关的比例尚不清楚。
从 1054 名 BRCA 突变阴性的遗传性 BC 西班牙裔女性(BC 诊断年龄<51 岁,双侧 BC、乳腺和卵巢癌,或 BC 诊断年龄 51-70 岁,有≥2 位一级或二级亲属在 70 岁之前诊断为 BC)、312 名当地对照和 887 名多民族队列对照的种系 DNA 进行测序和分析,以确定 12 个已知和可疑的、高外显率和中外显率的癌症易感性基因(共济失调毛细血管扩张突变 [ATM]、乳腺癌 1 相互作用蛋白 C 端解旋酶 1 [BRIP1]、钙粘蛋白 1 [CDH1]、检查点激酶 2 [CHEK2]、核蛋白 [NBN]、神经纤维瘤病 1 [NF1]、BRCA2 的伙伴和定位器 [PALB2]、磷酸酶和张力蛋白同源物 [PTEN]、RAD51 平行物 3 [RAD51C]、RAD51D、丝氨酸/苏氨酸激酶 11 [STK11] 和 TP53)。
在 1054 名参与者中的 47 名(4.6%)中发现了 49 个(4.6%)致病性或可能致病性变异(PV),包括 21 个截断移码、20 个错义、5 个无义和 4 个剪接变异,在 CHEK2(n=20)、PALB2(n=18)、ATM(n=5)、TP53(n=3)、BRIP1(n=2)和 CDH1 和 NF1(均 n=1)中均发现了这些变异,但在 NBN、PTEN、STK11、RAD51C 或 RAD51D 中均未发现这些变异。9 名参与者携带 PALB2 c.2167_2168del PV(0.85%),14 名参与者携带 CHEK2 c.707T>C PV(1.32%)。
在 1054 名 BRCA 阴性的高危西班牙裔女性中,4.5%携带癌症易感性基因的 PV,这增加了对该人群遗传性 BC 的了解。PALB2 和 CHEK2 中的复发性 PV 占总数的 47%(49 个中的 23 个),表明存在一个创始效应。通过仔细控制血统,以及更准确地识别有风险的西班牙裔人进行筛查和预防,从而能够准确分类变异。